6 Critical Reports Clinical Operations QuartzBio_

6 Critical Discrepancy Reports for Effective Clinical Operations

February 9, 2022 — Clinical operations leaders use the QuartzBio® virtual Sample Inventory Management (vSIM) solution to maintain robust visibility across sample collection and processing status, consent status, and sample and derivative quality information.

Traditionally, generating these reports is frustratingly time-consuming – often involving spreadsheets that attempt to manually link key information from the EDC, central labs, testing labs, and biorepositories to illuminate critical information like discrepancies or missed collections.

The QuartzBio team has identified six critical on-study reports that our clients prioritize as absolutely required for effective sample and biomarker operations.

Read More →
feb162022 webinar image

Webinar On Demand: Keeping Track of Clinical Samples in Biomarker-Rich Clinical Trials

Register for the webinar here

Title: Keeping Track of Clinical Samples in Biomarker-Rich Clinical Trials

Duration: 30 minutes

Learn how clinical operations and translational teams are creating “sponsor-centric” visibility to reconcile sample status and location on-study.

Read More →
SCOPE 2022 IMAGE

Join QuartzBio at the SCOPE 2022 Summit for Clinical Operations Executives

Join QuartzBio at the SCOPE 2022 Summit for the “Clinical Biomarkers Operations and Innovation” track on February 8-9.

PRESENTATION: "30 Days to an Annotated Virtual Repository -- Without Changing DTAs"

Clinical and biomarker operations teams can create ongoing visibility into sample collection, processing and testing by linking biospecimen metadata, informed consent, and biomarker data across multiple LIMS and inventories.
Mike Waters will share how teams are using technology to access a single source of truth for sample inventory management.

Read More →
Breadth Depth Use case BDM image 20220118

From IHC to Immune Profiling: Managing Data Breadth and Depth to Inform On-Study Decisions

January 10, 2022 — With immuno-oncology assets progressing in the clinic, a growing biotechnology company we work with faces an increasingly common challenge:

Their trials are generating large datasets across a wide range of assay modalities (Figure 1), but the data remains siloed.

In addition to clinical data coming from the clinical research organization (CRO), the velocity of data coming from an assay services laboratory continuously delivering biomarker data from flow cytometry, immunohistochemistry, and genomics platforms quickly becomes overwhelming. Still another, separate data stream comes from a specialty laboratory delivering T-cell receptor (TCR) profiling data.

Read More →